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8 ABSTRACT
19 Matrix degradation has a major impact on the release kinetics of drug delivery
20 systems. Regarding ordered mesoporous silica materials for biomedical appli-
21 cations, their dissolution is an important parameter that should be taken into
22 consideration. In this paper, we review the main factors that govern the
23 mesoporous silica dissolution in physiological environments. We also provide
24 the necessary knowledge to researchers in the area for tuning the dissolution
25 rate of those matrices, so the degradation could be controlled and the material
26 behaviour optimised.
27
28
29 Introduction
30 Ordered mesoporous silica materials (OMS) have
31 received great attention by the biomedical scientiﬁc
32 community since they were proposed for the ﬁrst
33 time as drug delivery systems by the research group
34 headed by Vallet-Regı´ et al. [1]. Their unique struc-
35 tural and textural properties, such as tuneable pore
36 structure, large surface area and pore volume, con-
37 trollable pore diameter and morphology, and func-
38 tionalisable surface, make OMS excellent candidates
39 to be applied as drug delivery devices in different
40 biomedical applications [2–5].
41 Initially, OMS were purposed as bioceramics for
42 local drug delivery and bone tissue regenerations due
43 to their surface characteristics, such as biocompati-
44 bility and bioactivity, and their capability to load and
45 release in a controlled fashion different therapeutic
46cargoes for the treatment of diverse pathologies
47(Fig. 1, top) [6–8]. The most widely employed OMS
48explored for such applications were MCM-41, SBA-15
49and MCM-48.
50OMS can be prepared with different morphologies,
51such as bulk [9, 10], ﬁbres [11, 12], rods [13, 14], ﬁlms
52[15, 16], monoliths [17, 18], spheres [19]. Among
53them, mesoporous silica nanoparticles (MSNs), with
54sizes in the 20–300 nm range, have found many
55applications in nanomedicine (Fig. 1, bottom),
56underlining their systemic administration as
57nanocarriers for diagnosis and treatment of complex
58diseases such as cancer [20–25].
59The degradability of different drug delivery devi-
60ces is a key parameter for their successful translation
61to a clinical scenario. In this sense, dissolution has
62profound implications in the mechanical properties
63of materials used for bone ﬁlling. Most importantly,
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Figure 1 Schematic depiction of the most relevant applications of OMS: in bulk, highlighting local drug delivery and bone tissue
regeneration purposes (top); and as MSNs incorporating different moieties according to the foreseen use (bottom).
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64 the degradation of the drug delivery matrix will
65 modify its drug release kinetics, as well as it can be
66 deeply important for its toxicity [26]. Despite all of
67 the extensive research that has been carried out on
68 OMS for biomedical applications, the degradation of
69 these materials has been much less studied. In fact, in
70 most of the recent research articles regarding OMS
71 for biomedical application, little or no attention has
72 been paid to the stability of those materials in the
73 biological environment in which they would carry
74 out their function. This review intends to provide
75 some insight into the main design characteristics that
76 researchers should take into account to modulate
77 OMS stability for speciﬁc biomedical applications.
78 Some of the main factors that govern the dissolution
79 rate of mesoporous silica and that will be addressed
80 in this review can be found in Fig. 2.
81 Degradation of ordered mesoporous silica
82 OMS are composed of polycondensed silica tetrahe-
83 drons (SiO4) interconnected by siloxane bonds (–Si–
84 O–Si–) exhibiting different condensation degree and
85 therefore displaying reactive silanol groups (–SiOH)
86 on the surface. This silica network is characterised by
87 an amorphous structure at atomic level in a similar
88 way to conventional sol–gel glasses [27]. OMS are
89 structurally unique, exhibiting order at the meso-
90 scopic scale (2–50 nm) and disorder at the atomic
91scale. Thus, the pore channels formed within the
92materials are separated by amorphous silica walls
93and arranged periodically on lattices [28].
94Several authors have dedicated a great effort to
95investigate the dissolution of sol–gel derived silica
96matrices in physiological ﬂuids [29–34]. It was found
97that the dissolution of these sol–gel silica matrices
98exhibits several steps, mainly characterised by an
99initial surface burst erosion followed by a slow bulk
100degradation. It is postulated that the rates of bulk
101degradation depend on the physical–chemical char-
102acteristics of the condensed silica network [35].
103As a representative example of silica dissolution
104proﬁle, that of SBA-15 material under physiological
105conditions is displayed in Fig. 3. In this particular
106case, the curve is characterised by a relatively fast
107dissolution rate up to ca. 5 days followed by plateau
108in which the amount of silica released to the medium
109is minimal.
110Key factors that govern silica degradation
111from ordered mesoporous materials in bulk
112OMS in bulk have been mainly proposed for bone
113tissue repair applications due to their biocompatible
114and bioactive behaviour in physiological environ-
115ment and above all owing their capability to act as
116local drug delivery devices. For this reason, it
117becomes essential to investigate the degradation
118process of these matrices in physiological media. For
Figure 2 Main factors that
govern silica dissolution in
physiological fluids from OMS
both in bulk and as MSNs.
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119 a better understanding of the evolution of the surface
120 of OMS in bulk during the degradation process, an
121 exhaustive study by high-resolution transmission
122 electron microscopy (TEM) has been reported else-
123 where using SBA-15 (Fig. 4) [33]. The obtained results
124 reveal that during the initial burst effect up to 5 days
125 there is a decrease in the mesopore wall thickness;
126 meanwhile, the 2D-hexagonal structure with p6mm
127 plane group is preserved, as it can be observed in the
128 periodicity of the crystal lattice fringes in the direc-
129 tion perpendicular to the mesopores. However, after
130 longer time periods, a total loss of the mesoporous
131 structure occurs.
132 In fact, 29Si solid-state nuclear magnetic resonance
133 (NMR) studies carried out using MCM-41 and SBA-
13415 materials in bulk show a remarkable initial
135increase in Q2 ((OH)2Si=) and Q
3 ((OH)–Si:) species
136after 7 days of assay in aqueous medium [36]. This
137phenomenon can be ascribed to the water penetration
138within the mesopores, which provokes an increase in
139the number of silanol groups (–SiOH) due to the
140hydrolysis of siloxane (–O–Si–O–) bonds. This is in
141agreement with the decrease in the wall thickness
142observed from the TEM studies previously described
143for SBA-15 (Fig. 4). For longer periods of assay
144(21 days), there is an increment of Q4 species (SiO4),
145pointing to the repolymerisation of the silanol groups
146to produce siloxane bonds [36]. These ﬁndings agree
147with the silica release proﬁle described in Fig. 3,
148where the initial silica burst release effect is followed
149by a plateau where the silica dissolution evolves
150slowly.
151There are several factors that inﬂuence silica
152degradation from OMS in bulk: (1) textural and
153structural properties; (2) network condensation
154degree; (3) chemical composition; (4) surface func-
155tionalisation; and (5) physiological medium.
156Textural and structural properties
157Undoubtedly, the textural properties such as pore
158diameter, surface area and pore volume directly
159affect silica dissolution process from OMS in bulk.
160However, the number of published studies on this
161topic is scarce and there is great deal of controversy
162since it is difﬁcult to separate the inﬂuence of these
163factors from the silica network condensation degree,
164which are frequently tightly related [34]. As an
Figure 4 High-resolution TEM images showing the degradation
process of SBA-15-type mesoporous material in physiological
conditions (PBS) at different time periods (10 and 60 days). After
10 days, the wall thickness decreases while keeping the 2D-
hexagonal structure. However, long-term assay (60 days) demon-
strates the total loss of the ordered mesoporous structure.
Figure 3 Silica dissolution profile from SBA-15 under physio-
logical conditions (phosphate buffer saline, PBS) showing an
initial surface burst release followed by a slow matrix degradation.
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165 example, the effect of pore diameter increase on silica
166 dissolution when comparing the behaviour of MCM-
167 41 (*2.5 nm) and SBA-15 (*8 nm) in aqueous
168 medium has been reported [37]. This study revealed
169 that the larger the pore diameter, the faster the dif-
170 fusion of the ﬂuids through the mesochannels, and
171 therefore higher the reactivity [38].
172 Regarding the structural features of OMS in bulk,
173 3D cubic mesostructures such as MCM-48 are
174 expected to exhibit faster silica dissolution rates than
175 2D hexagonal mesostructures such as that of MCM-
176 41 or SBA-15 [39]. Nonetheless, there are not con-
177 cluding research works that avail this observation in
178 physiological media.
179 Network condensation degree
180 Since the silica dissolution in aqueous media involves
181 the nucleophilic attack of water molecules with the
182 siloxane (–Si–O–Si–) and silanol (–SiOH) groups of
183 the mesoporous material, the network condensation
184 degree plays a pivotal role into this process. Thus, the
185 lower the silica condensation degree, the higher the
186 silica dissolution rate. Therefore, several scientiﬁc
187 reports have shown that different parameters
188 involved in the synthesis of OMS, such as silica
189 source, pH, temperature, surfactant removal proce-
190 dure (calcination or solvent extraction), strongly
191 inﬂuence the silica degradation rate in physiological
192 media [40].
193 Chemical composition
194 The degradation rate of OMS is strongly related to the
195 chemical composition. Different strategies have been
196 reported in the literature that aimed at tailoring the
197 silica dissolution from these matrices by incorporat-
198 ing heteroatoms into the silica network. Among the
199 most relevant herein, we focus on calcium- and
200 phosphorous-doped OMS for their direct implication
201 in bone tissue regeneration processes, where new
202 bone formation and release of biological agents are
203 aimed.
204 In this sense, it has been reported that doping OMS
205 with different calcium oxide amounts helps to obtain
206 an adaptable degradation performance [41–44]. In
207 addition, the presence of CaO as network modiﬁer is
208 also a very important factor for the bioactivity pro-
209 cess, i.e. the formation of a hydroxycarbonate apatite
210 (HCA) layer on the surface of bioactive materials
211[45, 46]. The presence of CaO units into the SiO2
212network induces a decrease in the silica network
213condensation degree and consequently higher silica
214dissolution. This is in agreement with results derived
215from different investigations carried out on bioactive
216glasses in the SiO2–CaO–P2O5 system prepared by
217traditional melt-quench, sol–gel or evaporation-in-
218duced self-assembly (EISA) methods [47–49].
219Phosphorous incorporation into OMS has also been
220reported for SBA-15 and MCM-41 materials. These
221articles have revealed that the incorporation of PO4
222units in the mesoporous materials results in materials
223with reduced silica leaching in aqueous medium as
224well as an increased bioactivity and biocompatibility
225[50, 51]. These results could be explained by the
226increase in the cross-linking degree together with an
227increase in the acidity of the mesoporous silica net-
228work by Si substitutions by P atoms (formation of Si–
229O–P linkages). The creation of active centres Si–O–P
230would favour the bioactive process. In the case of
231multicomponent materials (SiO2–CaO–P2O5 systems),
232such as certain mesoporous bioactive glasses, inde-
233pendently of the presence of calcium phosphate
234clusters, the sole existence of orthophosphate ions
235restricts the amount of Ca2? ions available for mod-
236ifying the silica network [35]. This is because PO4
3-
237ions consume a signiﬁcant fraction of Ca2? modiﬁers
238for preserving charge balance, which leads to a
239reduction in the level of silicate network depoly-
240merisation and therefore decreases matrix solubility.
241Surface functionalisation
242The functionalisation of silica surface with organic
243moieties has been demonstrated to play a key role in
244modulating the reactivity of OMS. Moreover, the
245incorporation of diverse functionalities on the surface
246of OMS has been proven to be able to tune the silica
247leaching by creating a protecting barrier towards
248water molecules from physiological environments.
249This has been ascribed to an increase in the
250hydrophobic character of OMS. Figure 5 shows the
251degradation process in PBS, studied by TEM, after
25260 days of incubation of pure silica SBA-15 and SBA-
25315 functionalised by the post-synthesis grafting of
254different organosilanes containing methyl, octyl or
255aminopropyl groups [33]. TEM images clearly reveal
256the protective effect of organosilanes on structural
257features of SBA-15, showing that the well-ordered 2D-
258hexagonal structure is maintained during the long-
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259 term assay for SBA-15 functionalised with octyl chains
260 or aminopropyl groups, which are the organic moi-
261 eties exhibiting the highest relative hydrophobicity.
262 Physiological environment
263 The inﬂuence of physiological medium on the
264 degradation rate of OMS has been scarcely studied.
265 In this sense, in vitro degradation tests using
266 unmodiﬁed SBA-15 and SBA-15 functionalised with
267 different organosilanes have been carried out in three
268 different media, such as PBS, simulated body ﬂuid
269 (SBF) and Dulbecco’s modiﬁed Eagle’s medium
270 (DMEM). The obtained results showed that the
271complexity of the aqueous medium regarding the
272ionic composition and the presence or absence of
273proteins did not signiﬁcantly affect the silica lixivia-
274tion for unmodiﬁed SBA-15.
275Key factors that govern silica degradation
276from mesoporous silica nanoparticles
277OMS as MSNs are under extensive evaluation as
278carriers of drugs for biomedical application. The
279number of publications focused on controlling the
280cargo release by capping the pores is growing expo-
281nentially in the last years. However, there are not
282many studies evaluating the eventual dissolution of
Figure 5 TEM images
showing the degradation
process in physiological
conditions (PBS) after 60 days
of pure silica SBA-15 and
SBA-15 functionalised by
post-synthesis with different
alkoxysilanes. Pure silica
SBA-15 undergoes a total loss
of mesostructural order,
whereas SBA-15
functionalised with methyl
groups shows small ordered
domains of 2D-hexagonal
structure. SBA-15
functionalised with octyl
chains or aminopropyl groups
exhibit a well-ordered 2D-
hexagonal structure, which is
preserved after the long-term
assay.
J Mater Sci
Journal : 10853 - Large 10853 Dispatch : 13-1-2017 Pages : 11
Article No. : 787
h LE h TYPESET
MS Code : JMSC-D-16-05570 h CP h DISK4 4
A
u
th
o
r
 P
r
o
o
f
U
N
C
O
R
R
EC
T
ED
PR
O
O
F
283 the nanoparticles after cargo release, which is a
284 desirable feature of a drug delivery nanosystem. In
285 fact, it is well known that silica normally decomposes
286 into free silicon species in the form of harmless
287 monosilicic acid by-products that after entering the
288 bloodstream or lymph would be excreted by the
289 urine. This is why MSNs present fewer challenges for
290 long-term use than other nanocarriers that are not
291 metabolised [52]. For this reason, a thorough under-
292 standing of its solubility and biodegradability is of
293 outmost importance to ensure its biocompatibility
294 and efﬁcacy for different pathological conditions.
295 Figure 6 shows micrographs of 200 nm MSNs dis-
296 persed in PBS for different periods of time.
297 Nanoparticle degradation can be clearly observed
298 after a few days in aqueous suspension.
299 Braun et al. [53] have recently evaluated the dis-
300 solution of MSNs of different sizes (80, 200 and
301 1500 nm). The dissolution proﬁle of the nanoparticles
302 was similar independently of the size of the particles.
303 They found a much slower dissolution for non-por-
304 ous silica, although that was the only sample without
305 thermal treatment post-synthesis (all mesoporous
306 materials were calcined). Yamada et al. [54] also
307 evaluated the degradation process of MSNs of dif-
308 ferent sizes (20–80 nm), and they also found that the
309 degradation process was independent of the particle
310 size.
311In a similar way to OMS in bulk, MSN solubility in
312aqueous media has also been observed to depend on
313several factors, such as morphology, surface area and
314functionalisation.
315Nanoparticle morphology
316Hao et al. [55] evaluated the inﬂuence of the
317nanoparticle morphology on its degradability. They
318studied nanoparticles with different aspect ratios
319(AR), from spheres (AR = 1) to rods (AR = 2 and
320AR = 4). They found that nanospheres were more
321rapidly dissolved than nanorods. The authors sug-
322gest that sphere-shaped MSNs underwent faster
323dissolution due to their relative larger outer surface
324area compared to rod-shaped MSNs.
325Surface area
326The surface area of the MSNs is also expected to play
327a key role in the dissolution kinetics of the nanopar-
328ticles. In this sense, the higher is the surface area the
329greater contact with the physiological ﬂuid at the
330interfaces, which leads to higher dissolution rates.
331This trend was observed by Townley and co-workers,
332who evaluated the solubility of two types of MSNs:
333blackberry-like MSNs (surface area of 303 m2/g) and
334chrysanthemum-like MSNs (surface area of 934 m2/
Figure 6 TEM micrographs of MSNs after suspension in PBS for different periods of time (from left to right): 0, 5, 8, 12 days (a),
schematic representation of the dissolution process of MSNs in aqueous medium (b).
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335 g) under a phosphate-buffered saline solution [52].
336 After incubation at 37 C, the samples were periodi-
337 cally removed for TEM imaging, observing that
338 nanoparticles with the lowest surface area were the
339 least degraded, as expected.
340 Chemical composition
341 The effect in nanoparticle degradability of different
342 chemical modiﬁcations of MSNs has also been stud-
343 ied by different authors. Shi et al. [56] reported that
344 Ca-doped MSNs have a faster degradation rate than
345 undoped MSNs. Fontecave et al. [57] reported that
346 mesoporous mixed silica–zirconia oxides followed
347 slower dissolution kinetics than pure mesoporous
348 silica. In the case of calcium-doped systems, the
349 decrease in the connectivity of the silica network,
350 because of the increase in non-bridging oxygens,
351 leads to a faster dissolution rate [56]. However, for
352 silica–zirconia systems, dissolved silica in the med-
353 ium cannot reach the saturation level due to the
354 recondensation of silica on local zirconium centres in
355 the mesoporous matrix [57].
356 Some work has been done to ease the degradation
357 of nanoparticles once they have performed their
358 function. Maggini et al. [58] recently reported
359 breakable MSNs by introducing redox-cleavable
360 disulphide bonds inside the silica network that
361 induced the loss of particle structure when exposed
362 to a reducing environment (like the intracellular
363 medium). This particle self-destruction would then
364 facilitate the degradation and excretion of the
365 resulting smaller particles.
366 Surface functionalisation
367 Cauda et al. [59] evaluated the dissolution of colloidal
368 MSNs in SBF up to 1 month. In that work, the authors
369 evaluated non-functionalised silica as well as phenyl-,
370 chloropropyl-, aminopropyl-functionalised nanopar-
371 ticles and PEG-coated nanoparticles. They found that
372 the fastest-degrading material was phenyl-function-
373 alised mesoporous silica, while PEG coating signiﬁ-
374 cantly reduced the dissolution rate as well as it
375 decreased the formation of hydroxyapatite-like
376 material on the nanoparticle surface. They also
377 observed that, during the dissolution process, there
378 was an increase in pore size and a decrease in porosity
379 and surface area of the nanoparticles. Hao et al. [55]
380 also studied the effect of PEG on MSN degradation
381and found a slower degradation of PEGylated
382nanoparticles and also a change in the dissolution
383process itself. While naked MSNs were dissolved
384from the external surface towards the inside, PEGy-
385lated nanoparticles started dissolving from the inside
386of the nanoparticle, advancing then towards the
387external surface. Cauda et al. [60] also evaluated the
388inﬂuence in the dissolution process of MSNs with
389covalently grafted PEG of different molecular weights
390(550 and 5000 Da). They found that denser and longer
391polymer chains slowed down the dissolution of the
392silica in a more efﬁcient manner. Recently, our
393research group has reported similar results regarding
394degradation of polymer-coated MSNs, with a signiﬁ-
395cantly slower silica dissolution when functionalised
396with a copolymer [61].
397Physiological environment
398The liquid medium in which the MSNs are dispersed
399is another key parameter regarding silica stability.
400Braun et al. [52] evaluated MSN degradation in
401simulated lung ﬂuid (SLF), SBF, simulated gastric
402ﬂuid (SGF) and PBS. They found the fastest dissolu-
403tion rate in SLF, with similar behaviour in PBS or SBF
404and the slowest degradation in SGF. Hao et al. [55]
405also evaluated the effect of foetal bovine serum on
406nanoparticle stability. They showed that proteins
407from the serum accelerated the dissolution process,
408decreasing nanoparticle stability. This factor is of
409foremost importance when regarding the biomedical
410application of these nanoparticles, since they will be
411in contact with a very wide variety of proteins in the
412biological environment.
413In vivo dissolution
414He et al. [62] evaluated the biodistribution,
415biodegradation and excretion of MSNs with different
416sizes (80–360 nm) and with or without PEG coating.
417They evaluated the concentration of products of silica
418degradation in urine, at different time points after tail
419vein injection of the MSNs. They found that the
420excreted amount of degradation products decreased
421with time for all of the materials tested. They
422observed a signiﬁcantly lower amount of degradation
423products for smaller nanoparticles, and for a given
424size, a slower degradation was seen for PEGylated
425MSNs. The authors attributed that behaviour to an
426easier capture by liver and spleen of MSNs with
AQ4
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427 larger particle size, while PEGylation would diminish
428 their accumulation in those organs and increase their
429 circulation time.
430 Conclusions
431 From the data presented in the literature regarding
432 ordered mesoporous silica dissolution in physiologi-
433 cal environments, it can be concluded that OMS
434 materials for drug delivery will suffer degradation, as
435 observed both in bulk and in nanoparticles. How-
436 ever, nanoparticle degradation will take place faster
437 than in bulk. The rate at which that dissolution takes
438 place can be tuned by carefully designing the mate-
439 rial characteristics, from textural and morphological
440 properties of the materials to post-synthesis modiﬁ-
441 cations directed to control silica dissolution. Fur-
442 thermore, the speciﬁc physiological environment will
443 also modify the dissolution behaviour. This implies
444 that each particular material should be designed
445 taking into account the environment at which it will
446 be exposed (either in a local implant or to be sys-
447 temically administered) in order to optimise the
448 degradation behaviour of the material to allow the
449 correct development of its desired function.
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